LEADER (trial)

The pivotal Phase 3 trials and post-approval cardiovascular, kidney, and sleep-apnea outcome studies.

Definition

First GLP-1 cardiovascular outcomes trial to show MACE reduction. N=9,340 adults with type 2 diabetes + established CVD or high CV risk, randomized to liraglutide vs placebo for median 3.8 years (Marso 2016 NEJM, PMID 27295427). Primary endpoint MACE HR 0.87 (P=0.01). Established the GLP-1-class cardioprotective paradigm before SUSTAIN-6 (semaglutide) confirmed it.

LEADER trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Major trials

STEP-1
SURMOUNT-1
SELECT
FLOW
SURMOUNT-OSA
STEP-TEENS
MACE (Major Adverse Cardiovascular Events)
KCCQ-CSS (Kansas City Cardiomyopathy Questionnaire — Clinical Summary Score)
ATTAIN-1
IWQOL-Lite-CT
STEP-4 (withdrawal trial)
SYNERGY-NASH
FLOW (trial)

Looking for more depth?

LEADER trial deep-dive
Browse the full GLP-1 glossary (124 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers